Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
Would you not also take into consideration the assets on the balance sheet? In addition to cash there is 17m of machinery. Which you would expect for a plant hire company. If they can buy more plant and turn a profit on it then that is good news surely, along with the debt needed to buy that plant.
Lotto, great find. Aerotoken in the US just one example of how blockchain could be used in the drone industry. Very interesting to read up on it but difficult to tell if it's a goer or not. Lots of info here for those interested https://www.smithandcrown.com/sale/aero-token-ico-dubious-prospects-drone-superhighway/ . Many other possibilities of course. Will be very interesting to see the new strategy when it's released.
Trundle, welcome to the discussion and indeed to LSE. Your first post, I see. I'm happy to think of those as minimums. As you say new activity will increase revenue. I look forward to upgrading my numbers when the interims come out.
I'm reckoning revenue of 4.5 and 2.5 so $7m a month for 18 H2. Current FY of $75 and 2018/19 target of $95. But I am aware that is more conservative than others. Gotnomoney is only bringing a bit if balance to the chat and I welcome that. The debt levels are of importance and we know that we have an unwelcome facility with Hermes put in place by the previous Board. Current and long term debt at June 17 of about $19m was approximately balanced by value of machinery and cash. For a plant hire company this seems entirely reasonable. In fact, as the Board have announced, they are currently investing in more machinery. All to the good. If there is profit to be made by having more then it makes good sense. Ability to service debt and reduce from profits is the key thing and the recent accounts clearly demonstrate that both are happening. Hopefully the interims will cast a bit of light on this. The big thing for me is not revenue it's EPS. Which is stated after finance costs. EPS currently running at an annualised rate of 2.8p gives a current p/e of 3. Forward looking p/e of 2. What's not to like?
This afternoon. Double figures next week
I don't think they need to raise cash. 2017 H2 they made nearly $1m profit after tax in 6 months with increasing revenues into 2018 H1. Paying off debt monthly. The only reason they might have need cash is for set up costs when they are awarded the $23m UN tender and they would be best off doing that with a short term loan. Talk of needing to raise cash is misleading.
Thanks Trade, very reassuring to know that the vast majority of the outstanding warrants are held by BoD so not going to be sold on exercise. Good news.
Thanks. I've just been through all the recent RNS's and your 1.1B issued and 85M and 35M exercised looks right. That leaves a further 890M still to come with an expiry date of 5 June. Whilst we are well above the exercise price we can assume that all these will be exercised. Good for the cash balance as there is a total of £311,500 still to come. All adds to the coffers. Downside I suppose is more cheap dilution and we don't know how many of the 890M will be sold straight away like this lot were.
Anyone keeping tabs on how many warrants are still out there?
Another little nugget from the December trading update: The markets which BPH and MRSSG service are the strongest they have been in years. BPH is currently working at fully capacity and has a strong pipeline of work to complete. MRSSG is experiencing strong demand, with revenues now exceeding $4.0m per month. So we should be looking at current full year revenues in excess of $75m...
From the trading update on 20 December: For FY18, first half expectations are for Profit after Tax and earnings per share to exceed $2.2m and 0.8p respectively, whilst for the full year earnings per share of not less than 2.0p are in prospect. Further progress is anticipated in 2018-19as debt continues to be repaid from the strong operational cash-flow generated by the major changes which are now taking effect. Full year eps of not less than 2p. So let's conservatively say 2.2p. With 0.8p in the first half that means that eps in the second half will be at least 1.4p or an annualised rate of 2.8p. Further progress for next year should mean eps for 2018/19 of 3.0 to 3.5p. Conservative estimates that don't take into consideration future growth with both sections of the business booming. On a forward eps of 3.5p that puts us on a p/e of 2... Dyor but if that isn't a screaming buy I don't know what is.
I don't think the market has really digested the last set if news yet. Just repeating it and confirming current year EPS in excess of 2p should be enough to keep this ticking up.
That would fit. We had EOY and trading update only 3 weeks ago so wouldn't expect another scheduled update until H1 and trading update probably in March. Of course unforeseen contract wins etc could easily come before then. All good. Sit back and watch it climb.